With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

A real-life study suggests that stepping down mepolizumab dosage in EGPA patients in remission is effective, with no asthma ...

Results of the study showed that 51.1% of benralizumab-treated patients compared with 45.4% of mepolizumab-treated patients attained a complete or partial response at 3 months. Notably, the complete ...

GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it ...

UK pharma major GSK (LSE: GSK) has published results from its Phase III MATINEE trial evaluating Nucala (mepolizumab) in ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.